Icon (NASDAQ:ICLR) Price Target Raised to $160.00 at BMO Capital Markets

Icon (NASDAQ:ICLR) had its price objective raised by BMO Capital Markets from $130.00 to $160.00 in a research report released on Friday,Benzinga reports. The brokerage currently has an outperform rating on the medical research company’s stock.

Other analysts also recently issued reports about the stock. TD Cowen raised shares of Icon from a “hold” rating to a “buy” rating and reduced their price target for the company from $183.00 to $120.00 in a report on Wednesday, February 18th. Piper Sandler downgraded shares of Icon to a “neutral” rating in a report on Thursday. Rothschild & Co Redburn set a $100.00 price target on shares of Icon and gave the company a “neutral” rating in a report on Tuesday, February 17th. Robert W. Baird set a $119.00 price target on shares of Icon in a report on Friday, February 13th. Finally, Weiss Ratings downgraded shares of Icon from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 18th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $153.00.

Icon Stock Performance

ICLR opened at $136.07 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The stock’s 50 day moving average price is $113.06 and its two-hundred day moving average price is $141.46. The firm has a market capitalization of $10.99 billion, a P/E ratio of 22.09, a price-to-earnings-growth ratio of 3.57 and a beta of 1.23. Icon has a 12-month low of $66.57 and a 12-month high of $211.00.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, June 3rd. The medical research company reported $2.52 EPS for the quarter, missing analysts’ consensus estimates of $3.13 by ($0.61). The business had revenue of $2.11 billion for the quarter, compared to analyst estimates of $1.98 billion. Icon had a return on equity of 10.58% and a net margin of 7.40%.The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the firm earned $3.43 earnings per share. On average, equities analysts forecast that Icon will post 11.53 earnings per share for the current year.

Hedge Funds Weigh In On Icon

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geneos Wealth Management Inc. raised its holdings in Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in Icon by 1.1% during the fourth quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock worth $899,000 after acquiring an additional 56 shares in the last quarter. Signaturefd LLC raised its holdings in Icon by 12.6% during the fourth quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock worth $117,000 after acquiring an additional 72 shares in the last quarter. New Wave Wealth Advisors LLC raised its holdings in Icon by 5.1% during the fourth quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock worth $270,000 after acquiring an additional 72 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its stake in Icon by 0.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock valued at $4,363,000 after buying an additional 93 shares during the period. Institutional investors own 95.61% of the company’s stock.

Key Headlines Impacting Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: BMO Capital Markets raised its target on Icon Plc to $160 from $130 and kept an outperform rating, suggesting meaningful upside potential. Benzinga
• Positive Sentiment: Barclays lifted its price target to $150 from $120, with an equal weight rating, signaling improved expectations for the stock. Tickerreport.com
• Positive Sentiment: Citigroup increased its target to $140 from $120, implying modest upside from current levels, though it kept a neutral stance. Tickerreport.com
• Neutral Sentiment: JPMorgan raised its target to $130 from $120 but kept a neutral rating, reflecting a more cautious view than some peers. Benzinga
• Neutral Sentiment: Icon reported fourth-quarter earnings that missed estimates, but revenue came in above expectations and the company highlighted strong bookings despite ongoing revenue challenges. Yahoo Finance
• Negative Sentiment: Icon disclosed a material weakness in internal controls, which raises concerns about financial reporting quality and potential regulatory risk. TipRanks
• Negative Sentiment: The company also cut FY 2026 EPS guidance to $10.00-$11.00, below Wall Street expectations, which likely pressured the stock after earnings. Financial News

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.